Hoffmann Sebastian, Rockenstein Andreas, Ramaswamy Anette, Celik Ilhan, Wunderlich Anette, Lingelbach Susanne, Hofbauer Lorenz C, Zielke Andreas
Department of Surgery, Philipps-University of Marburg, Baldingerstrasse, 35043 Marburg, Germany.
Mol Cell Endocrinol. 2007 Jan 29;264(1-2):74-81. doi: 10.1016/j.mce.2006.10.009. Epub 2006 Nov 13.
The anti-proliferative effect of retinoic acid (RA) has been documented for various tumors. Some 40% of patients with advanced and poorly differentiated thyroid cancer have been shown to respond to RA with increased uptake of radioiodine. It has been suggested that these effects may be caused by redifferentiation. Presently, little is known about the effects of RA on tumor angiogenesis, a prerequisite for growth and metastatic spread. The aim of the current study was to determine, whether tumor-induced angiogenesis of thyroid cancer is affected by RA. In vitro, the effect of 0.1/10 microM 13-cis RA on tumor cell number (MTT assay) and secretion of VEGF (ELISA) was analyzed in three thyroid cancer cell lines (FTC 236, C634 and XTC), as well as in endothelial cells (HUVEC) over several passages. In vivo, tumor growth, VEGF-expression and microvessel density (VSD) of RA treated thyroid cancer cells after xenotransplantation to nude mice was evaluated by morphometric analysis. In vitro, thyroid cancer cell lines responded to RA with reduced proliferation, ranging from 26 to 34% after 2 weeks of treatment and with up to 80% reduced secretion of VEGF. In vivo, tumor volumes of animals receiving RA were reduced by 33% (FTC 236), 27% (C643) and 6% (XTC), respectively. VSD of experimental tumors was diminished in the FTC 236 (25%) and the C643 cell line (15%), and almost unchanged in XTC tumors (7%). In vivo, VEGF-expression and apoptosis were not significantly affected by RA. In vitro, proliferation of HUVEC was inhibited by conditioned medium of C643 cells pretreated with RA (0.1/10 microM), as well as by administration of RA (0.1/10 microM). This study confirms thyroid tumor cell growth to be inhibited by RA. It demonstrates a decrease of in vitro VEGF accumulation and reduction of VSD in experimental undifferentiated thyroid carcinoma, suggesting that reduced angiogenesis may be an important mechanism responsible for the therapeutic effect of RA in thyroid cancer. Moreover, a direct anti-proliferative effect of RA on human endothelial cells is suggested.
维甲酸(RA)对多种肿瘤的抗增殖作用已有文献记载。约40%的晚期低分化甲状腺癌患者对RA有反应,表现为放射性碘摄取增加。有人认为这些作用可能是由再分化引起的。目前,关于RA对肿瘤血管生成(生长和转移扩散的一个先决条件)的影响知之甚少。本研究的目的是确定甲状腺癌的肿瘤诱导血管生成是否受RA影响。在体外,分析了0.1/10微摩尔13 - 顺式RA对三种甲状腺癌细胞系(FTC 236、C634和XTC)以及内皮细胞(HUVEC)在多个传代过程中肿瘤细胞数量(MTT法)和VEGF分泌(ELISA)的影响。在体内,通过形态计量分析评估了将RA处理的甲状腺癌细胞异种移植到裸鼠后肿瘤的生长、VEGF表达和微血管密度(VSD)。在体外,甲状腺癌细胞系对RA有反应,增殖减少,治疗2周后减少26%至34%,VEGF分泌最多减少80%。在体内,接受RA的动物的肿瘤体积分别减少了33%(FTC 236)、27%(C643)和6%(XTC)。实验性肿瘤的VSD在FTC 236(25%)和C643细胞系(15%)中减少,在XTC肿瘤中几乎不变(7%)。在体内,VEGF表达和细胞凋亡未受RA显著影响。在体外,用RA(0.1/10微摩尔)预处理的C643细胞的条件培养基以及给予RA(0.1/10微摩尔)均可抑制HUVEC的增殖。本研究证实RA可抑制甲状腺肿瘤细胞生长。它表明在实验性未分化甲状腺癌中体外VEGF积累减少和VSD降低,提示血管生成减少可能是RA对甲状腺癌治疗作用的重要机制。此外,提示RA对人内皮细胞有直接抗增殖作用。